logo-loader
viewHotel Chocolat Group

Hotel Chocolat sees jump in revenue and expects trading to be ‘in line with expectations’

In a trading update for the 52 weeks ended 1 July 2018, the AIM-listed firm said its revenue was £116mln, a 12% increase compared to the same period a year ago

Hotel chocolat store front
The company said it has developed a number of innovative new products for the upcoming season

Hotel Chocolat Group PLC (LON:HOTC) has announced a jump in revenue, boosted by opening new stores and growing online buyers, and said it expects pre-tax profit to be in line with market expectations.

In a trading update for the 52 weeks ended 1 July 2018, the AIM-listed firm said its revenue was £116mln, a 12% increase compared to the same period a year ago.

READ: Hotel Chocolat sees profits, sales jump 15%, boosted by new store openings, digital growth

The chocolatier said the business opened 15 stores in the year, contributing 6% to year-on-year sales and added 200,000 new online buyers.

The company said it has developed a number of innovative new products for the upcoming autumn-winter season.

Angus Thirlwell, co-founder and chief executive officer of Hotel Chocolat, said: "Hotel Chocolat has had another strong year. Customers are continuing to respond well to our luxury brand and lifestyle propositions. During the recent heatwave in the UK, our new Chilled Chocolat drinks, unique Chocs to Chill, Ice Cream of the Gods and improved Cocoa Beers have been very popular.”

He added: "The deep knowledge of our School of Chocolate-trained retail teams and our experiential Chocolate Lock-in sessions continue to underpin the allure of our multi-channel model."

Quick facts: Hotel Chocolat Group

Price: 420.2499 GBX

AIM:HOTC
Market: AIM
Market Cap: £484 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

16 minutes ago

2 min read